Last reviewed 2026-04-22 · How we verify

Fengshigutong Capsule plus Imrecoxib

This combination product combines traditional Chinese medicine (Fengshigutong) with Imrecoxib, a selective COX-2 inhibitor, to reduce inflammation and pain in joint and musculoskeletal conditions.

This combination product combines traditional Chinese medicine (Fengshigutong) with Imrecoxib, a selective COX-2 inhibitor, to reduce inflammation and pain in joint and musculoskeletal conditions. Used for Rheumatoid arthritis, Osteoarthritis, Joint pain and inflammation.

At a glance

Mechanism of action

Fengshigutong Capsule is a traditional Chinese herbal formulation designed to address wind-damp-heat patterns associated with joint pain and inflammation. Imrecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces prostaglandin production and inflammatory mediators. The combination leverages both traditional herbal anti-inflammatory mechanisms and modern selective COX-2 inhibition for enhanced therapeutic effect in rheumatologic conditions.

Approved indications

• Rheumatoid arthritis
• Osteoarthritis
• Joint pain and inflammation

Common side effects

• Gastrointestinal upset
• Abdominal pain
• Dyspepsia
• Cardiovascular events (COX-2 inhibitor class risk)

Key clinical trials

• A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Fengshigutong Capsule plus Imrecoxib CI brief — competitive landscape report
• Fengshigutong Capsule plus Imrecoxib updates RSS · CI watch RSS
• Sun Yat-sen University portfolio CI